Presurgical serum albumin levels predict survival time from glioblastoma multiforme

Journal of Neuro-Oncology

Volumn 43, Issue 1, 1999, Pages 35-41

  Schwartzbaum, Judith A ^a,b   Lal, Priya ^a   Evanoff, Wendi ^d   Mamrak, Sandra ^a   Yates, Allan ^a   Barnett, Gene H ^d   Goodman, Joseph ^c   Fisher, James L ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cox proportional hazards regression model; Glioblastoma multiforme; Serum albumin; Survival analysis

Indexed keywords

SERUM ALBUMIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; DEMOGRAPHY; FEMALE; GLIOBLASTOMA; HUMAN; MALE; PREDICTION; PREOPERATIVE PERIOD; PROGNOSIS; REGRESSION ANALYSIS; SURVIVAL TIME;

FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PREOPERATIVE CARE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SERUM ALBUMIN; SURVIVAL RATE;

EID: 0032781719     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006269413998     Document Type: Article

References (29)

1. Giles GG, Gonzales MF: Epidemiology of brain tumors and factors in prognosis. In: Kaye AH, Laws, ER Jr (eds) Brain Tumors: An Encyclopedic Approach. Churchill Livingstone: New York, 1995, pp 47-67
2. Salmon I, Dewitte O, Pasteels J-L, Flament-Durand J, Brotchi J, Vereerstraeten P, Kiss R: Prognostic scoring in adult astrocytic tumors using patient age, histopathological grade, and DNA histogram type. J Neurosurg 80: 877-883, 1994
3. Rainov NG, Dobberstein K-U, Bahn H, Holzhausen H-J, Lautenschlager C, Heidecke V, Burkert W: Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neurooncol 35: 13-28, 1997
4. McKeever PE, Ross DA, Strawderman MS, Brunberg JA, Greenberg HS, Junck L: A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferation cell nuclear antigen with histopathologic and clinical parameters. J Neuropathol Exp Neurol 56: 798-805, 1997
5. Salcman M: Glioblastoma and malignant astrocytoma. In: Kaye AH, Laws, ER Jr (eds) Brain Tumors: An Encyclopedic Approach. Churchill Livingstone: New York, 1995, pp 449-447
6. Falconer JS, Fearon KCH, Ross JA, Elton R, Wigmore SJ, Garden J, Carter DC: Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 75: 2077-2082, 1994
7. Gough DB, Fearon KCH, Carter DC: Metabolic disturbance and sensitivity of endotoxin in patients with advanced cancer: relationship to lymphocyte reactivity, tumor necrosis factor (TNF) production and survival. Clin Exp Immunol 105: 529-539, 1996
8. Pasqualetti P, Collacciani A, Maccarone C, Casale R: Prognostic factors in multiple myeloma: selection using Cox's proportional hazard model. Biomed and Pharmacother 50: 29-25, 1996
9. Citterio G, Bertuzzi A, Tresoldi M., Galli, Di Lucca G, Scaglietti U, Rugarli C: Prognostic factors for survival in metastatic renal cell carcinoma: Retrospective analysis from 109 consecutive patients. Eur Urol 31: 286-291, 1997
10. Maltoni M, Pirovano M, Nanni O, Marinari M, Indelli M, Gramazio A, Terzoli E, Luzzani M, De Marinis F, Caraceni A, Labianca R, and Italian multicenter study group on palliative care. Biological indices predictive of survival in 519 Italian terminally ill cancer patients. J Pain Symptom Manage 13: 1-9, 1997
11. Maestu I, Pastor M, Gomez-Codina J, Aparicio J, Oltra A, Herranz C, Montalar J, Munarriz B, Reynes G: Pretreatment prognostic factors for survival in small-cell lung cancer: A new prognostic index and validation of three known prognostic indices on 341 patients. Ann Oncol 8: 547-553, 1997
12. Bastion Y, Sebban C, Berger F, Felan P, Salles G, Dumontet C, Bryon PA, Coiffer B: Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 15: 1587-1594, 1997
13. Mackiewicz A: Acute phase proteins and transformed cells. Int Rev Cytol 170: 225-296, 1997
14. Seymour JF, Talpaz M, Hagemeister FB, Cabanillas F, Kurzrock R: Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's Disease. Am J Med 102: 21-28, 1997
15. Thiounn N, Pages F, Flam T, Tartour E, Mosseri V, Zerbib M, Beuzeboc P, Deneux L, Fridman WH, Debre B: IL-6 is a survival prognostic factor in renal cell carcinoma. Immunol Lett 58: 121-4, 1997
16. Neugut AI, Fink DJ, Radin D: Serum cholesterol and primary brain tumors: A case-control study. Int J Epidemiol 18: 798-801, 1989
17. Wolff JEA, Molenkamp G, Hotfilder M, Laterra J: Dexamethasone inhibits glioma-induced formation of capillary like structures in vitro and angiogenesis in vivo. Klin Padiatr 209: 275-277, 1997
18. Freshney RI: Effects of glucocorticoids on gliomas cells in culture; Minireview on cancer research. Expl Cell Biol 52: 286-289, 1984
19. Weissman DE, Dufer D, Vogel V, Abeloff MD: Corticosteroid toxicity in neuro-oncology patients. J Neurooncol 5: 125-128, 1987
20. Tontsch U, Bauer HC: Glial cells and neurons induce blood-brain barrier related enzymes in cultured cerebral endothelial cells. Brain Res 539: 247-253, 1991
21. Sattar N, Scott HR, McMillan DC, Talwar D, O'Reilly SJ, Fell GS: Acute-phase reactants and plasma trace element concentrations in non-small cell lung cancer patients and controls. Nutr Cancer 28: 308-312, 1997
22. Rothman KJ, Greenland S: Modern Epidemiology. Lippincott-Raven, Philadelphia, 1998
23. Shapiro WR, Shapiro JR: Biology and treatment of malignant glioma. Oncology 12: 233-240, 1998
24. Giometto B, Bozza F, Faresin F, Alessio L, Mingrino S, Tavolato B: Immune infiltrates and cytokines in gliomas. Acta Neurochirurgica 138: 50-56, 1996
25. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ: Interleukin 6 induces expression of vascular endothelial growth factor. J Biol Chem 271: 736-41, 1996
26. Merzak A, Pilkington GJ: Molecular and cellular pathology of intrinsic brain tumors. Canc Met Rev 16: 155-177, 1997
27. Abdulrauf SI, Edvardsen K, Ho Kl, Yang XY, Rock JP, Rosenbium ML: Vascular endothelial growth factor expression and vascular density as prognostic markers of survival of patients with low-grade astrocytoma. J Neurosurg 88: 513-20, 1998
28. Tjuvajev J, Uehara H, Desai R, Beattie B, Matei C, Zhou Y, Kreek M-J, Koutcher J, Blasberg R: Corticotropin-releasing factor decreases vasogenic brain edema. Cancer Res 56: 1352-1360, 1996
29. Hocks GM, Barry D, Fey GR: Synergistic action of interleukin-6 and glucocorticoids is mediated by the interleukin-6 response element of the rat alpha 2 macroglobulin gene. Mol Cell Biol 12: 2282-2294, 1992